Mission Statement, Vision, & Core Values (2026) of Sirio Pharma Co., Ltd.

From its founding in 1993 to its Shenzhen Stock Exchange listing in 2019 (stock code 300791.SZ), Sirio Pharma Co., Ltd. has grown into a globally recognized CDMO in nutraceuticals with over 30 years of expansion, operating nine automated production bases and five R&D centers worldwide and delivering end-to-end services-from research and product development to manufacturing, packaging, logistics and marketing-while its mission to "advance nutrition science and technology, deliver value to health" and vision to be "an innovation leader in nutrition science and technology, first choice of customers" drive investments in cutting-edge formats (softgels, plant-based softgels, gummies, beadlets) and strategic partnerships that enhance customer-centric innovation; anchored by core values of integrity, innovation, quality, sustainability and collaboration, Sirio's sustainability programs have already achieved a 20% reduction in carbon emissions over the past year, underscoring how measurable operational goals, robust R&D and global manufacturing scale align to meet evolving consumer health needs

Sirio Pharma Co., Ltd. (300791.SZ) - Intro

• Established: 1993; Shenzhen Stock Exchange listing: 2019 (300791.SZ).
• Global footprint: 9 automated production bases, 5 R&D centers, operations across Asia, Europe and North America.
• Workforce & scale: ~1,800 employees; products exported to 60+ countries and regions.

• Mission: Deliver scientifically validated, high-quality nutraceutical solutions that improve global health through integrated R&D, scalable manufacturing and sustainable operations.
• Vision: Be the partner-of-choice for scalable, innovative nutraceutical manufacturing - enabling brands to launch safer, more effective products faster and sustainably.
• Core values:
  • Science-first: evidence-driven formulation and quality control.
  • Customer partnership: co-development, IP protection and supply reliability.
  • Sustainability: energy efficiency, emissions reduction and circular practices.
  • Integrity & compliance: global GMP, regulatory alignment and traceability.

• Dosage forms: softgels (classic & plant-based), gummies, beadlets, tablets, powders and liquids.
• Services: formulation R&D, clinical support, stability testing, scale-up, automated packaging and cold-chain logistics.
• Strategic partnerships: collaborations with leading domestic and international enterprises for raw materials, clinical research and distribution.

• Carbon reduction: 20% reduction in scope 1-2 emissions over the past year via energy-efficient upgrades and increased renewable procurement.
• Waste & water: stepped-up recycling and wastewater-treatment investments across production bases to minimize environmental footprint.
• Social: workforce training programs, supplier audits and community health initiatives in manufacturing regions.

• Product innovation: expand plant-based softgels and precision-delivery beadlets to capture premium market segments.
• Capacity scaling: commissioning additional automated lines to reduce lead times and support large-volume contracts.
• Global regulatory alignment: invest in multi-jurisdictional registrations (FDA, EFSA-equivalent processes) to broaden addressable markets.
• Sustainability integration: continue energy transition and circular packaging initiatives to meet customer ESG mandates.

Sirio Pharma Co., Ltd. (300791.SZ) - Overview

• Science-led product pipeline: emphasis on evidence-based formulations and clinical studies to substantiate health claims.
• Technology integration: investment in extraction, bioavailability enhancement, and quality-control automation.
• Value to health: prioritization of products with measurable biomarkers, therapeutic adjunct potential, or clear consumer health benefits.
• Global reach: expansion into Southeast Asia, Europe, and select North American channels while maintaining a strong domestic presence.

• Increasing R&D intensity: targeting >=8% of revenue within 3 years to accelerate clinically backed product launches.
• Pipeline translation: converting active R&D projects into commercial SKUs, with priority on high-margin therapeutic nutrition segments.
• Quality and compliance: expanding GMP-certified manufacturing capacity and international regulatory clearances to support export growth.
• Partnerships and M&A: selective collaborations with universities, contract research organizations, and strategic acquisitions to secure proprietary ingredients and technologies.

• Clinical validation: multiple randomized controlled trials and biomarker studies underway to substantiate efficacy of core products.
• Manufacturing scale: multi-site production footprint with increasing automation to maintain margins as volumes grow.
• Commercial channels: diversified go-to-market via B2B institutional sales, cross-border e-commerce, and branded retail distribution.

Sirio Pharma Co., Ltd. (300791.SZ) - Mission Statement

• Innovation leadership through proprietary formulation and process technologies.
• Customer-first orientation: custom development, fast scale-up, and regulatory support.
• Quality and compliance: GMP, ISO, and targeted international registrations to enable export growth.

• Science-driven: R&D-led product roadmap that prioritizes bioavailability and stability improvements.
• Integrity & compliance: robust QA/QC and traceability across supply chains.
• Sustainability & responsibility: focus on plant-based solutions and reduced environmental footprint in manufacturing.

• Allocate a multi-year R&D budget to advance plant-based excipients and encapsulation tech.
• Expand pilot and scale production capacity to reduce customer time-to-market and enable higher-mix manufacturing.
• Pursue targeted regulatory filings and international certifications to open export corridors and strategic accounts.

• Plant-based softgels: commercialized formulations for vegan supplementation segments, increasing addressable market share in specialty channels.
• Beadlets and microencapsulation: improving shelf-stability and dosing accuracy for lipophilic actives; enabling higher-margin finished goods partnerships.
• Customer co-development programs: shorter development cycles and recurring OEM contracts that enhance revenue visibility.

• Market positioning: technology-first specialty manufacturer with exposure to growing global nutraceutical demand.
• Growth levers: new product adoption (plant-based softgels), capacity scale, and international certifications to drive export mix uplift.
• Engagement: transparent investor communications and operational targets help align shareholders with the innovation-led strategy.

Sirio Pharma Co., Ltd. (300791.SZ) - Vision Statement

• Integrity: prioritizing ethical practices, regulatory transparency, and compliance across GMP sites and supply chains.
• Innovation: sustained investment into R&D to develop formulation platforms, novel delivery systems, and process intensification.
• Quality: rigorous QA/QC frameworks and third‑party audits to ensure product safety and efficacy.
• Sustainability: operational initiatives to reduce environmental impact, including a reported 20% reduction in carbon emissions year‑over‑year.
• Collaboration: strategic partnerships with universities, CROs, and industry leaders to accelerate product development and scale‑up.

• Ethical governance: strengthened compliance programs, expanded quality management systems, and transparent reporting to investors and regulators.
• R&D acceleration: allocating ~12% of revenue to R&D to advance 15+ pipeline projects and in‑licensing collaborations annually.
• Quality assurance: maintaining GMP certification across facilities and reducing batch deviation rates by targeted percentages year over year.
• Sustainable operations: energy efficiency upgrades, waste minimization programs, and measurable targets (20% carbon cut achieved; roadmap to net‑zero planning).
• Partnerships & open innovation: co‑development agreements with academic labs and industrial partners to shorten time‑to‑market and broaden technical capabilities.